Drug market

A drug market is the network of production, distribution, and sale through which a substance actually reaches people — the full supply chain from synthesis or cultivation to the point of use. Harm reduction treats markets as a primary variable because purity, potency, and adulteration are properties of the supply chain, not of the compound itself.

What circulates under a given name at any moment reflects who is producing it, how, and through what intermediaries — none of which the name alone discloses. A substance that is genuine in one batch, cut in the next, and substituted entirely in a third is not an unusual event; it is a predictable consequence of unregulated supply.

How it is done

Drug markets are typically structured in layers: upstream producers (clandestine laboratories, diverted pharmaceutical supply, or illicit importation), wholesale distributors who consolidate and repackage, and retail sellers at the point of use. Adulteration or substitution can occur at any layer, and downstream buyers often have no means of detecting it.

Harm reduction organisations and public health agencies track circulating supply through drug checking services — reagent tests or laboratory analysis at service points — combined with analysis of confiscated samples and community alert networks that distribute findings across regions.

Different market segments carry different risk profiles. Markets built on pharmaceutical diversion tend to show lower substitution risk than clandestine synthesis markets, where batch composition can vary widely between production runs. The proliferation of novel psychoactive substances has added a third category: compounds with little prior documentation, sold under existing names or as unlabelled alternatives.

What it cannot tell you

Market-level information establishes what has been found in a supply or region over a period of time — it cannot establish what is in a specific sample. An alert describing an adulterant in a regional supply documents that the adulterant has been found somewhere in that supply; it does not confirm that any particular sample is affected.

The most consequential wrong conclusion from a clean market signal is safety by absence: if no alerts have been issued, a supply is assumed to be uncontaminated. Drug markets are not comprehensively surveilled, and absence of alerts reflects the limits of monitoring rather than the actual state of the supply.

Market data also cannot correct for batch-to-batch variability. A source that has previously provided unadulterated substance carries no guarantee of consistency on a subsequent purchase. Supply conditions shift faster than surveillance can track them.